Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping (S22.001)

Francesco Muntoni, Diane Frank, Valentina Sardone, Jenny Morgan, Fred Schnell, Jay Charleston, Cody Desjardins, Rahul Phadke, Caroline Sewry, Linda Popplewell, Michela Guglieri, Kate Bushby, Pierre Carlier, Chris Clark, George Dickson, Jean-Yves Hogrel, Volker Straub, Eugenio Mercuri, Thomas Voit, Edward Kaye, Laurent Servais
First published April 9, 2018,
Francesco Muntoni
1University College London London United Kingdom
2Great Ormond Street Hospital London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Frank
3Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Sardone
1University College London London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Morgan
1University College London London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Schnell
3Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay Charleston
3Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cody Desjardins
3Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahul Phadke
1University College London London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Sewry
1University College London London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Popplewell
4Royal Holloway University of London Egham United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michela Guglieri
5Newcastle University Newcastle upon Tyne United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Bushby
5Newcastle University Newcastle upon Tyne United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Carlier
6Institut de Myologie Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Clark
1University College London London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Dickson
4Royal Holloway University of London Egham United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Yves Hogrel
6Institut de Myologie Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Volker Straub
5Newcastle University Newcastle upon Tyne United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugenio Mercuri
7Universitá Cattolica del Sacro Cuore Roma Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Voit
6Institut de Myologie Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Kaye
3Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Servais
6Institut de Myologie Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping (S22.001)
Francesco Muntoni, Diane Frank, Valentina Sardone, Jenny Morgan, Fred Schnell, Jay Charleston, Cody Desjardins, Rahul Phadke, Caroline Sewry, Linda Popplewell, Michela Guglieri, Kate Bushby, Pierre Carlier, Chris Clark, George Dickson, Jean-Yves Hogrel, Volker Straub, Eugenio Mercuri, Thomas Voit, Edward Kaye, Laurent Servais
Neurology Apr 2018, 90 (15 Supplement) S22.001;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To conduct an analysis of exon 53 skipping and dystrophin production and its cellular localization in muscle biopsies from patients in an ongoing trial of golodirsen (formerly SRP-4053).

Background: Golodirsen is a phosphorodiamidate morpholino oligomer (PMO) that binds and excludes exon 53 during dystrophin mRNA processing, enabling production of internally shortened dystrophin protein. A first-in-human multicenter trial is evaluating the safety, tolerability, and efficacy of golodirsen through 144 weeks of treatment in Duchenne muscular dystrophy (DMD) patients with a genetic mutation amenable to exon 53 skipping.

Design/Methods: In a preplanned interim analysis, paired muscle biopsies of the biceps brachii were obtained at baseline and Week 48 from 25 patients receiving weekly intravenous infusions of golodirsen 30 mg/kg. Biopsies were examined using a validated Western blot method to quantify dystrophin production (primary biological end point). Exon 53 skipping was evaluated using reverse transcription polymerase chain reaction (RT-PCR). An automated image analysis (MuscleMap™) used immunohistochemistry to assess dystrophin localization and sarcolemma fiber intensity.

Results: Mean percent of normal dystrophin protein increased from 0.095% at baseline to 1.019% at Week 48 (range: 0.09%–4.30%), a significant mean change of +0.924% (P<0.001). Muscle biopsy samples from all 25 patients displayed a significant increase from baseline in exon 53 skipping via RT-PCR at Week 48 (P<0.001), demonstrating the intended mechanism of action. A positive correlation between exon 53 skipping and de novo dystrophin production was observed (Spearman-r = 0.500; P=0.011). Analysis of mean fiber intensity demonstrated a significant increase from baseline in de novo dystrophin production (P<0.001) and confirmed dystrophin sarcolemma localization.

Conclusions: Golodirsen increased exon 53 skipping, dystrophin production, and dystrophin sarcolemma localization in all patients. Golodirsen is the second PMO shown to increase dystrophin expression and membrane localization through the initiation of exon skipping, further strengthening the potential utility of the PMO technology platform in DMD.

Study Supported by: Study supported by Sarepta Therapeutics.

Disclosure: Dr. Muntoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Participation to SAB meetings (Roche; Avexis and Biogen) and educational activities (Biogen). Dr. Muntoni has received research support from My institute receives support for Biogen and Roche sponsored clinical trials. Dr. Frank has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Sardone has nothing to disclose. Dr. Morgan has nothing to disclose. Dr. Schnell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Charleston has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Desjardins has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Phadke has nothing to disclose. Dr. Sewry has nothing to disclose. Dr. Popplewell has nothing to disclose. Dr. Guglieri has nothing to disclose. Dr. Bushby has nothing to disclose. Dr. Carlier has nothing to disclose. Dr. Clark has nothing to disclose. Dr. Dickson has nothing to disclose. Dr. Hogrel has nothing to disclose. Dr. Straub has nothing to disclose. Dr. Mercuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen MA, Inc, Ionis Pharmaceuticals, Inc. & F. Hoffman La-Roche Ltd. Dr. Voit has nothing to disclose. Dr. Kaye has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Servais has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Avexis, Sarepta, Dynacure, Pfizer, Servier. Dr. Servais has received research support from Roche, Valerion, Dynacure.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise